Author, year | Prevalence of CrAg positivity | Incidence of CM | All-cause mortality | |||||||
CD4<100 (cells/μL) | CD4 100 ~ 200 (cells/μL) | CD4<100 (cells/μL) | CD4 100 ~ 200 (cells/μL) | CD4<100 (cells/μL) | CD4 100 ~ 200 (cells/μL) | |||||
with antifungal treatment | without antifungal treatment | with antifungal treatment | without antifungal treatment | with antifungal treatment | without antifungal treatment | with antifungal treatment | without antifungal treatment | |||
Chariyalertsak, 2002 [25] | Not reported | 0 of 40 | 6 of 45 | 0 of 23 | 0 of 21 | Not reported | Not reported | |||
Parkes-Ratanshi, 2011 [18] | Not reported | 17 of 698 | 2 of 821 | 3a of 698 | 0a of 821 | |||||
McKinsey, 1999 [19] | Not reported | 0 of 101 | 7 of 103 | 1 of 48 | 1 of 43 | Not reported | Not reported | |||
Meya, 2010 [21] | 26 of 295 | 7 of 298 | 3 of 21 | 2 of 5 | Not reported | 6 of 21 | 5 of 5 | 0 of 4 | 1 of 3 | |
Govender, 2015 [1] | 20 of 708 | 6 of 371 | Not reported | Not reported | Not reported | Not reported | ||||
Borges, 2019 [24] | 12 of 159 | 5 of 5 | 0 of 9 | 0 of 3 | 0 of 1 | 1 of 4 | Not reported | Not reported | ||
Pooled CrAg + prevalence: 0.06 [−0.02, 0.11], p = 0.001, I2 = 86.5% | Pooled CrAg + prevalence: 0.02 [0.01, 0.03], p = 0.146, I2 = 48% | Risk ratio with 95%CI: 7.67 [2.03, 29.05], p = 0.36, I2 = 1% | Risk ratio with 95%CI: 1.15 [0.16, 8.13], p = 0.97, I2 = 0% | Risk ratio with 95%CI: 0.32 [0.16, 0.64], p and I2 not applicable | Risk ratio with 95%CI: 0.27 [0.01, 4.93], p and I2 not applicable | |||||
Risk ratio with 95%CI | 1.82 [0.77, 4.30], p = 0.007, I2 = 63% | 2.53 [0.50, 12.71], p = 0.26, I2 = 59% | 4.15 [0.89, 19.42], p = 0.07, I2 = 0% |